



Nanomedicine & Immunotherapy: The Grail for Cancer Treatment?

Guest Editors:

Dr. Cátia Domingues

Dr. Ana Figueiras

Dr. Ivana Jarak

Deadline for manuscript
submissions:

closed (30 September 2024)

Message from the Guest Editors

Cancer continues to represent a significant socio-economic and health problem worldwide. Despite the advances in diagnosis and treatment, most patients do not respond to or become resistant to conventional treatments or relapse. The advent of immunotherapy has encouraged patient-targeted treatment. However, some gaps in knowledge remain, namely cancer immune editing/exhaustion issues and adverse immunotoxicity events. Therefore, combining conventional therapies with nanomedicine has gained ground in the scientific community. Nanomedicine explores the potential of applying nanotechnology to medicine via triggering the release of cargos, such as imaging and therapeutic agents, for cancer-patient-personalized diagnosis, treatment, and monitoring. Consequently, merging immunotherapy and nanomedicine may constitute a direction for improving cancer diagnosis and treatment, focusing on cancer cells and the surrounding tumor microenvironment.

Hence, cordially invite researchers to submit original research or review manuscripts that present up-to-date data on immunotherapy and nanomedicine applications for cancer prevention and management.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)